Payment overview · 2025
General Payments
$407.53
19 reported records · 12 companies
Healthcare provider profile · identity verified
Richele Williams, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHELBYVILLE, KY · NPI 1396367009
Verified facts
What the public records show
CMS Open Payments records show Richele Williams, MD received $407.53 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.50 | 17.3% | 3 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $45.00 | 11.0% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $43.88 | 10.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.06 | 10.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.89 | 10.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$38.35 | 9.4% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.06 | 7.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.78 | 6.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.87 | 5.4% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.11 | 5.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.97 | 3.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.06 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $407.53 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $45.00 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.27 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $43.88 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.06 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $38.35 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 111 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 82 | 16 |
| Lisinopril | Lisinopril | 64 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | suppressed |
| Eliquis | Apixaban | 41 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 18 |
| Furosemide | Furosemide | 39 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Losartan Potassium | Losartan Potassium | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | 14 |
| Omeprazole | Omeprazole | 30 | 12 |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 15 |
| Azithromycin | Azithromycin | 26 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Gabapentin | Gabapentin | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 18 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Prednisone | Prednisone | 23 | 21 |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Valsartan | Valsartan | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $407.53 · 19 records | ABBVIE INC. | CAPLYTA, FANAPT, HETLIOZ, Heplisav-B, KISUNLA, MINIMED 780G, MOUNJARO, OTEZLA, Ohtuvayre, Omnipod, QULIPTA, REPATHA, REXULTI, SPRAVATO, UBRELVY, VRAYLAR, ZEPBOUND, ZORYVE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error